Millipore Sigma Vibrant Logo
Attenzione: Ci siamo trasferiti. Non è più possibile acquistare i prodotti Merck Millipore nel sito MerckMillipore.comPer saperne di più

OP20 Anti-c-Abl (Ab-3) Mouse mAb (24-21)

Anti-c-Abl (Ab-3), mouse monoclonal, clone 24-21, recognizes the ~145 kDa human and ~150 kDa mouse c-Abl. It is validated for Western blotting, immunofluorescence, and immunoprecipitation.

Anti-c-Abl (Ab-3) Mouse mAb (24-21): MSDS (material safety data sheet) o SDS, certificato d’analisi (CoA) e certificato di qualità (CoQ), dossier, brochure e altri documenti disponibili.

Sinonimi: Anti-p150, Anti-Abl

OP20
Purchase on Sigma-Aldrich

Panoramica

Replacement Information

Tabella delle specifiche principali

Species ReactivityHostAntibody Type
H, MMMonoclonal Antibody

Products

Numero di catalogoConfezionamento Qtà/conf
OP20-100UG Fiala di plastica 100 μg
Description
OverviewRecognizes the ~145 kDa human c-Abl, the ~150 kDa mouse c-Abl, v-Abl, and the Bcr/Abl translocation products in ALL (~190 kDa) and CML (~210 kDa). Does not inhibit protein tyrosine kinase activity.
  • Antibody Target Gene Symbol: ABL1
  • Target Synonym: ABL, AI325092, bcr/abl, C-ABL, C-ABL 1B, CABL1, E430008G22Rik, JTK7, MGC117749, p145Abl, p150, v-abl
  • Entrez Gene Name: c-abl oncogene 1, receptor tyrosine kinase
  • Hu Entrez ID: 25 (Related Antibodies: PK1006 PK1013 OP19)
  • Mu Entrez ID: 11350
  • Rat Entrez ID: 311860
    		•
    Catalogue NumberOP20
    Brand Family Calbiochem®
    SynonymsAnti-p150, Anti-Abl
    References
    ReferencesWiedemann, L.M., et al. 1988. Blood 71, 349.
    Stam, K., et al. 1985. N. Engl. J. Med. 313, 1429.
    Konopka, J.B., et al. 1984. Cell 37, 1035.
    Prywes, R., et al. 1983. Cell 34, 569.
    de Klein, A., et al. 1982. Nature 300, 765.
    Reynolds, F.H., Jr., et al. 1980. J. Virol. 36, 374.
    Reynolds, F.H., Jr., et al. 1978. Proc. Natl. Acad. Sci. USA 75, 3974.
    Witte, O.N., et al. 1978. Proc. Natl. Acad. Sci. USA 75, 2488.
    Abelson, H.T. and Rabstein, L.S. 1970. Cancer Res. 30, 2213.
    Product Information
    FormLiquid
    FormulationIn 0.05 M sodium phosphate buffer, 0.2% gelatin, pH 7.5.
    Positive controlK562 (human bcr/abl), HL-60 (normal abl), and ANN-1 (murine abl) cells
    Preservative≤0.1% sodium azide
    Quality LevelMQ100
    Applications
    Application ReferencesOriginal Clone Schiff-Maker, L., et al. 1986. J. Virol. 57, 1182. Immunofluorescence Schiff-Maker, L. and Rosenberg, N. 1986. Virol. 154, 286.
    Key Applications Immunoblotting (Western Blotting)
    Immunofluorescence
    Immunoprecipitation
    Not Neutralization Studies
    Application NotesImmunoblotting (1-5 µg/ml)
    Immunofluorescence (see application references)
    Immunoprecipitation (1-2 µg/sample)
    Neutralization Studies (not recommended)
    Application CommentsDoes not inhibit protein tyrosine kinase activity. Detects human c-Abl (145 kDa), mouse c-Abl (150 kDa), v-Abl, and the Bcr/Abl translocation products in ALL (~210 kDa) and CML (~190 kDa). HL-60 and NIH3T3 cells contain normal, non-rearranged protein. Antibody should be titrated for optimal results in individual sample types.
    Biological Information
    Immunogena recombinant protein consisting of the carboxyl region of v-abl protein fused to TrpE
    Clone24-21
    HostMouse
    IsotypeIgG₁
    Species Reactivity
    • Human
    • Mouse
    Antibody TypeMonoclonal Antibody
    Concentration Label Please refer to vial label for lot-specific concentration
    Physicochemical Information
    Dimensions
    Materials Information
    Toxicological Information
    Safety Information according to GHS
    Safety Information
    Product Usage Statements
    Storage and Shipping Information
    Ship Code Blue Ice Only
    Toxicity Standard Handling
    Storage +2°C to +8°C
    Do not freeze Yes
    Packaging Information
    Transport Information
    Supplemental Information
    Specifications
    Global Trade Item Number
    Numero di catalogo GTIN
    OP20-100UG 04055977208900

    Documentation

    Anti-c-Abl (Ab-3) Mouse mAb (24-21) Certificati d'Analisi

    TitoloNumero di lotto
    OP20

    Riferimenti bibliografici

    Panoramica delle referenze
    Wiedemann, L.M., et al. 1988. Blood 71, 349.
    Stam, K., et al. 1985. N. Engl. J. Med. 313, 1429.
    Konopka, J.B., et al. 1984. Cell 37, 1035.
    Prywes, R., et al. 1983. Cell 34, 569.
    de Klein, A., et al. 1982. Nature 300, 765.
    Reynolds, F.H., Jr., et al. 1980. J. Virol. 36, 374.
    Reynolds, F.H., Jr., et al. 1978. Proc. Natl. Acad. Sci. USA 75, 3974.
    Witte, O.N., et al. 1978. Proc. Natl. Acad. Sci. USA 75, 2488.
    Abelson, H.T. and Rabstein, L.S. 1970. Cancer Res. 30, 2213.

    Brochure

    Titolo
    Antibody Sourcebookﾙ Sixth Edition
    Scheda tecnica

    Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

    Revision02-October-2007 RFH
    SynonymsAnti-p150, Anti-Abl
    ApplicationImmunoblotting (1-5 µg/ml)
    Immunofluorescence (see application references)
    Immunoprecipitation (1-2 µg/sample)
    Neutralization Studies (not recommended)
    DescriptionPurified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with p.3U1 mouse myeloma cells (see application references). Recognizes the v-Abl, the ~145-150 kDa c-Abl, the ~210 kDa Bcr-Abl (CML), and the ~190 kDa Bcr-Abl (ALL) proteins.
    BackgroundThe abl oncogene was initially identified as the viral transforming gene (v abl) of Abelson murine leukemia virus (A-MuLV), from a chemically thymectomized mouse inoculated with Moloney murine leukemia virus (M MuLV). The v-abl genome consists of M-MuLV gag sequences fused to mouse c-abl, resulting in the production of phosphoproteins, p160 and p120 gag/c-abl with protein-tyrosine kinase activity, as the major translational products. The abl oncogene is implicated in several human leukemias including 90-95% of chronic myelocytic (CML), 20-25% of adult acute lymphoblastic (ALL), and 2-5% of pediatric ALL. In these leukemias the c-abl proto-oncogene undergoes a chromosomal (9;22) translocation producing the Philadelphia (Ph1) chromosome resulting in the fusion of c-abl sequences to the bcr gene of chromosome 22. The molecular consequences of this translocation is the generation of a chimeric bcr/c-abl mRNA encoding activated abl protein-tyrosine kinase.
    HostMouse
    Immunogena recombinant protein consisting of the carboxyl region of v-abl protein fused to TrpE
    Clone24-21
    IsotypeIgG₁
    Specieshuman, mouse
    Positive controlK562 (human bcr/abl), HL-60 (normal abl), and ANN-1 (murine abl) cells
    FormLiquid
    FormulationIn 0.05 M sodium phosphate buffer, 0.2% gelatin, pH 7.5.
    Concentration Label Please refer to vial label for lot-specific concentration
    Preservative≤0.1% sodium azide
    CommentsDoes not inhibit protein tyrosine kinase activity. Detects human c-Abl (145 kDa), mouse c-Abl (150 kDa), v-Abl, and the Bcr/Abl translocation products in ALL (~210 kDa) and CML (~190 kDa). HL-60 and NIH3T3 cells contain normal, non-rearranged protein. Antibody should be titrated for optimal results in individual sample types.
    Storage +2°C to +8°C
    Do Not Freeze Yes
    Toxicity Standard Handling
    ReferencesWiedemann, L.M., et al. 1988. Blood 71, 349.
    Stam, K., et al. 1985. N. Engl. J. Med. 313, 1429.
    Konopka, J.B., et al. 1984. Cell 37, 1035.
    Prywes, R., et al. 1983. Cell 34, 569.
    de Klein, A., et al. 1982. Nature 300, 765.
    Reynolds, F.H., Jr., et al. 1980. J. Virol. 36, 374.
    Reynolds, F.H., Jr., et al. 1978. Proc. Natl. Acad. Sci. USA 75, 3974.
    Witte, O.N., et al. 1978. Proc. Natl. Acad. Sci. USA 75, 2488.
    Abelson, H.T. and Rabstein, L.S. 1970. Cancer Res. 30, 2213.
    Application referencesOriginal Clone Schiff-Maker, L., et al. 1986. J. Virol. 57, 1182. Immunofluorescence Schiff-Maker, L. and Rosenberg, N. 1986. Virol. 154, 286.